Video: Whitehead Connects - An Evening with David Meeker

December 10, 2018

Tags: Awards + Announcements

During this Whitehead Connects presentation, David Meeker discusses innovation and biopharmaceutical pricing. Meeker is the President & CEO of KSQ, a biotech company with a proprietary CRISPRomics drug discovery engine. Meeker was formerly the President and CEO of Genzyme, a Sanofi company, a position he assumed when Genzyme merged with Sanofi in 2011. He was also a member of the executive committee.

Meeker is the Chairman of the Board of Rhythm Pharmaceuticals and Trevi Therapeutics and a member of the board at Myokardia. He also serves on the boards of the Biomedical Science Careers Program, the Network for Excellence in Health Innovation and the Dimock Center, a Boston based community health center.

© Whitehead Institute for Biomedical Research              455 Main Street          Cambridge, MA 02142